GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » Other Long Term Assets
Switch to:

Biogen (BUE:BIIB) Other Long Term Assets

: ARS239,391 Mil (As of Mar. 2023)
View and export this data going back to 2019. Start your Free Trial

Biogen's other long-term assets for the quarter that ended in Mar. 2023 was ARS239,391 Mil.

Biogen's quarterly other long-term assets increased from Sep. 2022 (ARS163,197 Mil) to Dec. 2022 (ARS205,606 Mil) and increased from Dec. 2022 (ARS205,606 Mil) to Mar. 2023 (ARS239,391 Mil).

Biogen's annual other long-term assets increased from Dec. 2020 (ARS111,450 Mil) to Dec. 2021 (ARS142,911 Mil) and increased from Dec. 2021 (ARS142,911 Mil) to Dec. 2022 (ARS205,606 Mil).


Biogen Other Long Term Assets Historical Data

The historical data trend for Biogen's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Long Term Assets
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 81,212.81 193,194.25 111,449.91 142,910.95 205,605.95

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Other Long Term Assets Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 138,381.10 148,691.78 163,196.77 205,605.95 239,391.10

Biogen Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.


Biogen (BUE:BIIB) Business Description

Biogen logo
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines